GLP-1 drugs and older adults: key evidence

GLP-1 receptor agonists have reshaped obesity and type 2 diabetes management, but most pivotal trials enrolled relatively younger adults. A review published in Advances in Therapy in July 2026 by Pendrey and colleagues examines what the literature actually says about using these agents in older populations, where the clinical picture is more complicated^[1]. The agents covered include tirzepatide, semaglutide, and liraglutide.

The review estimates that roughly 40% of older adults have obesity and 29% have type 2 diabetes, making this a large and underserved clinical group^[1]. GLP-1 receptor agonists work by suppressing appetite, improving insulin secretion, and slowing gastric emptying. In large trials of middle-aged adults, tirzepatide produced mean body-weight reductions of 15% to 20.9% at 72 weeks^[2], and semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks^[3]. But older patients bring a set of considerations those headline numbers do not capture.

Sarcopenia: the central concern

The most-cited concern in the review is sarcopenia, the age-related loss of skeletal muscle mass and strength. When older adults lose weight rapidly, they can lose disproportionate muscle relative to fat^[1]. This matters because skeletal muscle is a primary site of glucose uptake, and muscle loss in older adults is linked to falls, frailty, and reduced functional independence. The review notes that the major GLP-1 trials generally did not report muscle-mass endpoints, meaning clinicians are extrapolating from body-composition data that was not designed to answer this question.

What the literature does show is that weight loss on GLP-1 agents affects both fat and lean mass. In SURMOUNT-4, participants who continued tirzepatide past week 36 maintained their initial 21% average weight reduction; those switched to placebo regained roughly 14% of their body weight within 52 weeks. The composition of that regained weight is not established in the published data. For older patients, the practical implication is that resistance exercise alongside pharmacotherapy is widely recommended to protect muscle mass, though the combination has not been tested in large randomised trials in older adults specifically.

Polypharmacy and drug interactions

Older adults with obesity and type 2 diabetes typically take multiple medications. GLP-1 receptor agonists slow gastric emptying, which can alter the absorption timing of oral drugs^[1]. The review highlights that medications with narrow therapeutic windows, including oral anticoagulants and thyroid hormone preparations, may be affected. The practical guidance is careful monitoring when initiating a GLP-1 agent in a patient already managing several daily medications, not automatic exclusion.

Hypoglycaemia risk is another area that requires calibration in older patients. GLP-1 receptor agonists have a low intrinsic hypoglycaemia risk because their insulin-stimulating effects are glucose-dependent. However, when combined with sulfonylureas or insulin, the risk of hypoglycaemia rises, and older adults who fall as a result of a low blood sugar event face serious consequences. The review recommends dose review of concomitant hypoglycaemic agents when a GLP-1 agonist is added.

Cardiovascular benefit: relevant at any age

One area where the review is more optimistic is cardiovascular outcomes. The SELECT trial enrolled 17,604 adults with obesity and established cardiovascular disease but without diabetes. Among participants aged 45 and older, semaglutide 2.4 mg weekly reduced major adverse cardiovascular events by 20% relative to placebo over approximately 40 months of follow-up (hazard ratio 0.80)^[4]. Many of those enrolled fell into older age brackets, lending some external validity to use in the older adult population. Renal benefits have also been reported in cardiovascular outcome trials, which is relevant given the high prevalence of chronic kidney disease in older patients with type 2 diabetes.

The SUMMIT trial of tirzepatide in heart failure with preserved ejection fraction and obesity similarly included an older population by design. Over a median follow-up of 104 weeks, tirzepatide reduced the composite of cardiovascular death or worsening heart failure events compared to placebo (9.9% versus 15.3%, hazard ratio 0.62)^[5]. Heart failure with preserved ejection fraction is disproportionately common in older, obese women, making this trial particularly relevant to the population the review addresses.

Where the evidence is thin

The review is candid about what the literature does not yet have. Most GLP-1 agonist trials have set upper age limits or enrolled populations with mean ages in the mid-50s, leaving the 75-plus cohort largely unstudied^[1]. Specific data on falls, frailty outcomes, cognitive function, and muscle-mass preservation during weight loss are absent from the major trial programmes. Head-to-head comparisons in older adults specifically, comparing tirzepatide against semaglutide against liraglutide on geriatric endpoints, do not yet exist.

The conclusion of the review is measured: GLP-1 receptor agonists are a valuable treatment option for older adults with obesity and type 2 diabetes, and the cardiovascular and renal data support their use in appropriate patients. But the individualized approach required in geriatric medicine, accounting for frailty, muscle mass, polypharmacy, and functional status, demands more dedicated research than the field currently has.

This article is for educational and journalistic purposes only and does not constitute medical advice. Anyone considering a GLP-1 receptor agonist should discuss the decision with a qualified healthcare provider who knows their full medical history. Peptide products may be classified as prescription medicines in your jurisdiction.